Tagrisso met primary endpoint in phase III 2nd-line lung cancer trial
AstraZeneca announced that the Phase III AURA3 trial met its primary endpoint, demonstrating superior progression-free survival (PFS) compared to standard...
AstraZeneca announced that the Phase III AURA3 trial met its primary endpoint, demonstrating superior progression-free survival (PFS) compared to standard...
ViiV Healthcare presented 48-week data from the phase IIIb, open-label, international, multi-centre ARIA study which showed superior efficacy for Triumeq...
The Marketing Authorization Application (MAA) for SB5, an adalimumab biosimilar candidate referencing Humira®1, has been accepted for review by the...
Advanced Clinical has been recognized as a Silver Award recipient of PRO Unlimited’s Annual Global Supplier Awards. Recipients of this...
- Approval includes toric version of symfony iol for people with astigmatism- lenses provide high-quality continuous vision so patients can...
Abbott announced that Health Canada has approved the company's Absorb bioresorbable heart stent, making the first-of-its-kind medical device commercially available...
• Collaboration aims to develop PROteolysis TArgeting Chimeric molecules (PROTACs) – a new therapeutic modality that is able to degrade...
Eli Lilly and Company and Boehringer Ingelheim announced a new collaboration on a Phase 1b study that will evaluate the...
Janssen Pharmaceuticals, Inc one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), announced today that the U.S. Food...
Amgen and Daiichi Sankyo Company announced the execution of an exclusive agreement to commercialize nine biosimilars in Japan. The deal...
Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.
© 2017 Copyright © Valuemediaservices 2017 All rights reserved.